BioPorto (Denmark) Performance
| BIOPOR Stock | DKK 1.62 0.04 2.41% |
The firm shows a Beta (market volatility) of 0.0485, which signifies not very significant fluctuations relative to the market. As returns on the market increase, BioPorto's returns are expected to increase less than the market. However, during the bear market, the loss of holding BioPorto is expected to be smaller as well. At this point, BioPorto has a negative expected return of -0.36%. Please make sure to confirm BioPorto's potential upside, as well as the relationship between the rate of daily change and relative strength index , to decide if BioPorto performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days BioPorto has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 107.9 M | |
| Total Cashflows From Investing Activities | -412 K |
BioPorto |
BioPorto Relative Risk vs. Return Landscape
If you would invest 209.00 in BioPorto on August 25, 2024 and sell it today you would lose (47.00) from holding BioPorto or give up 22.49% of portfolio value over 90 days. BioPorto is generating negative expected returns and assumes 2.4902% volatility on return distribution over the 90 days horizon. Simply put, 22% of stocks are less volatile than BioPorto, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
BioPorto Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioPorto's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioPorto, and traders can use it to determine the average amount a BioPorto's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.145
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BIOPOR |
Estimated Market Risk
| 2.49 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.36 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BioPorto is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioPorto by adding BioPorto to a well-diversified portfolio.
BioPorto Fundamentals Growth
BioPorto Stock prices reflect investors' perceptions of the future prospects and financial health of BioPorto, and BioPorto fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioPorto Stock performance.
| Return On Equity | -0.88 | |||
| Return On Asset | -0.41 | |||
| Profit Margin | (2.50) % | |||
| Operating Margin | (2.82) % | |||
| Current Valuation | 753.23 M | |||
| Shares Outstanding | 334.68 M | |||
| Price To Earning | (16.82) X | |||
| Price To Book | 9.22 X | |||
| Price To Sales | 31.01 X | |||
| Revenue | 24.25 M | |||
| EBITDA | (58.6 M) | |||
| Cash And Equivalents | 32.21 M | |||
| Cash Per Share | 0.19 X | |||
| Total Debt | 1.99 M | |||
| Debt To Equity | 4.90 % | |||
| Book Value Per Share | 0.27 X | |||
| Cash Flow From Operations | (64.58 M) | |||
| Earnings Per Share | (0.21) X | |||
| Total Asset | 81.25 M | |||
| Retained Earnings | (91 M) | |||
| Current Asset | 42 M | |||
| Current Liabilities | 5 M | |||
About BioPorto Performance
By analyzing BioPorto's fundamental ratios, stakeholders can gain valuable insights into BioPorto's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if BioPorto has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioPorto has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
BioPorto AS, an in-vitro diagnostics company, provides diagnostic tests and antibodies for healthcare professionals in clinical and research settings worldwide. BioPorto AS was founded in 2000 and is headquartered in Hellerup, Denmark. BioPorto operates under Diagnostics Research classification in Denmark and is traded on Copenhagen Stock Exchange. It employs 31 people.Things to note about BioPorto performance evaluation
Checking the ongoing alerts about BioPorto for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioPorto help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioPorto generated a negative expected return over the last 90 days | |
| BioPorto may become a speculative penny stock | |
| The company reported the revenue of 24.25 M. Net Loss for the year was (57.11 M) with profit before overhead, payroll, taxes, and interest of 15.04 M. | |
| BioPorto has accumulated about 32.21 M in cash with (64.58 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.19. | |
| Roughly 20.0% of the company shares are held by company insiders |
- Analyzing BioPorto's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioPorto's stock is overvalued or undervalued compared to its peers.
- Examining BioPorto's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioPorto's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioPorto's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioPorto's stock. These opinions can provide insight into BioPorto's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for BioPorto Stock analysis
When running BioPorto's price analysis, check to measure BioPorto's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioPorto is operating at the current time. Most of BioPorto's value examination focuses on studying past and present price action to predict the probability of BioPorto's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioPorto's price. Additionally, you may evaluate how the addition of BioPorto to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Stocks Directory Find actively traded stocks across global markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |